HPV pathway profiling: HPV related cervical dysplasia and carcinoma studies

Susy M. Scholl, Maud Kamal, Léanne De Koning, A. Kereszt, Ekaterina S. Jordanova, Sergiu Ungureanu, Els Berns, Xavier Sastre

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cervical cancer is the second most common malignancy among women worldwide. While more than 90% of cervical cancers carry one or more high risk HPV types, the exact relationship between HPV oncoproteins and signaling pathways alterations in cervical cancer remains to be clarified. Vaccines and targeted therapies are today considered of great potential for the improvement of patients' outcome. This review will focus on the interaction of HPV with cervical cancer pathway activations. Next generation high throughput screening technologies for molecular and protein profiling as well as innovative logistics, necessary for the implementation of the personalized care of cervical cancer patients will be discussed.

Original languageEnglish
Pages (from-to)1379-1394
Number of pages16
JournalCurrent Pharmaceutical Design
Volume19
Issue number8
Publication statusPublished - 2013

Fingerprint

Uterine Cervical Dysplasia
Uterine Cervical Neoplasms
Carcinoma
Active Immunotherapy
Oncogene Proteins
Technology
Neoplasms
Proteins

Keywords

  • Cervical cancer
  • HPV
  • Omics
  • Targeted therapy
  • Vaccines

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Scholl, S. M., Kamal, M., De Koning, L., Kereszt, A., Jordanova, E. S., Ungureanu, S., ... Sastre, X. (2013). HPV pathway profiling: HPV related cervical dysplasia and carcinoma studies. Current Pharmaceutical Design, 19(8), 1379-1394.

HPV pathway profiling : HPV related cervical dysplasia and carcinoma studies. / Scholl, Susy M.; Kamal, Maud; De Koning, Léanne; Kereszt, A.; Jordanova, Ekaterina S.; Ungureanu, Sergiu; Berns, Els; Sastre, Xavier.

In: Current Pharmaceutical Design, Vol. 19, No. 8, 2013, p. 1379-1394.

Research output: Contribution to journalArticle

Scholl, SM, Kamal, M, De Koning, L, Kereszt, A, Jordanova, ES, Ungureanu, S, Berns, E & Sastre, X 2013, 'HPV pathway profiling: HPV related cervical dysplasia and carcinoma studies', Current Pharmaceutical Design, vol. 19, no. 8, pp. 1379-1394.
Scholl SM, Kamal M, De Koning L, Kereszt A, Jordanova ES, Ungureanu S et al. HPV pathway profiling: HPV related cervical dysplasia and carcinoma studies. Current Pharmaceutical Design. 2013;19(8):1379-1394.
Scholl, Susy M. ; Kamal, Maud ; De Koning, Léanne ; Kereszt, A. ; Jordanova, Ekaterina S. ; Ungureanu, Sergiu ; Berns, Els ; Sastre, Xavier. / HPV pathway profiling : HPV related cervical dysplasia and carcinoma studies. In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 8. pp. 1379-1394.
@article{1e6fef344c43467b82354bf31355e1da,
title = "HPV pathway profiling: HPV related cervical dysplasia and carcinoma studies",
abstract = "Cervical cancer is the second most common malignancy among women worldwide. While more than 90{\%} of cervical cancers carry one or more high risk HPV types, the exact relationship between HPV oncoproteins and signaling pathways alterations in cervical cancer remains to be clarified. Vaccines and targeted therapies are today considered of great potential for the improvement of patients' outcome. This review will focus on the interaction of HPV with cervical cancer pathway activations. Next generation high throughput screening technologies for molecular and protein profiling as well as innovative logistics, necessary for the implementation of the personalized care of cervical cancer patients will be discussed.",
keywords = "Cervical cancer, HPV, Omics, Targeted therapy, Vaccines",
author = "Scholl, {Susy M.} and Maud Kamal and {De Koning}, L{\'e}anne and A. Kereszt and Jordanova, {Ekaterina S.} and Sergiu Ungureanu and Els Berns and Xavier Sastre",
year = "2013",
language = "English",
volume = "19",
pages = "1379--1394",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - HPV pathway profiling

T2 - HPV related cervical dysplasia and carcinoma studies

AU - Scholl, Susy M.

AU - Kamal, Maud

AU - De Koning, Léanne

AU - Kereszt, A.

AU - Jordanova, Ekaterina S.

AU - Ungureanu, Sergiu

AU - Berns, Els

AU - Sastre, Xavier

PY - 2013

Y1 - 2013

N2 - Cervical cancer is the second most common malignancy among women worldwide. While more than 90% of cervical cancers carry one or more high risk HPV types, the exact relationship between HPV oncoproteins and signaling pathways alterations in cervical cancer remains to be clarified. Vaccines and targeted therapies are today considered of great potential for the improvement of patients' outcome. This review will focus on the interaction of HPV with cervical cancer pathway activations. Next generation high throughput screening technologies for molecular and protein profiling as well as innovative logistics, necessary for the implementation of the personalized care of cervical cancer patients will be discussed.

AB - Cervical cancer is the second most common malignancy among women worldwide. While more than 90% of cervical cancers carry one or more high risk HPV types, the exact relationship between HPV oncoproteins and signaling pathways alterations in cervical cancer remains to be clarified. Vaccines and targeted therapies are today considered of great potential for the improvement of patients' outcome. This review will focus on the interaction of HPV with cervical cancer pathway activations. Next generation high throughput screening technologies for molecular and protein profiling as well as innovative logistics, necessary for the implementation of the personalized care of cervical cancer patients will be discussed.

KW - Cervical cancer

KW - HPV

KW - Omics

KW - Targeted therapy

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84876718638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876718638&partnerID=8YFLogxK

M3 - Article

C2 - 23016770

AN - SCOPUS:84876718638

VL - 19

SP - 1379

EP - 1394

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 8

ER -